The therapeutic potential of O6-alkylguanine DNA alkyltransferase inhibitors.
Khan O. and Middleton MR., (2007), Expert Opin Investig Drugs, 16, 1573 - 1584
Immune thrombocytopenic purpura.
Psaila B. and Bussel JB., (2007), Hematol Oncol Clin North Am, 21, 743 - vii
MORC4, a novel member of the MORC family, is highly expressed in a subset of diffuse large B-cell lymphomas.
Liggins AP. et al, (2007), Br J Haematol, 138, 479 - 486
The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP.
Page LK. et al, (2007), Br J Haematol, 138, 245 - 248
A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer
Sabharwal A. et al, (2007), JOURNAL OF CLINICAL ONCOLOGY, 25
Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma.
Ranson M. et al, (2007), J Clin Oncol, 25, 2540 - 2545
Immature platelet fraction: Insight into mechanisms of response to treatment in immune thrombocytopenic purpura
Psaila B. et al, (2007), INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 29, 25 - 25
Eltrombopag, an oral platelet growth factor, for treatment of chronic immune thrombocytopenic purpura (ITP): A randomized, double-blind, placebo-controlled trial
Bussel JB. et al, (2007), Journal of Supportive Oncology, 5, 66 - 67
Targeting cell cycle kinases and kinesins in anticancer drug development.
Yap TA. et al, (2007), Expert Opin Drug Discov, 2, 539 - 560
Hospital staff should use more than one method to detect adverse events and potential adverse events: incident reporting, pharmacist surveillance and local real-time record review may all have a place.
Olsen S. et al, (2007), Qual Saf Health Care, 16, 40 - 44
Niche-to-niche migration of bone-marrow-derived cells.
Kaplan RN. et al, (2007), Trends Mol Med, 13, 72 - 81
Novel thrombopoietic agents.
Andemariam B. et al, (2007), Hematology Am Soc Hematol Educ Program, 106 - 113
The use of pharmacokinetic and pharmacodynamic end points to determine the dose of AQ4N, a novel hypoxic cell cytotoxin, given with fractionated radiotherapy in a phase I study
Steward WP. et al, (2007), Annals of Oncology, 18, 1098 - 1103
Bone marrow cells in the 'pre-metastatic niche': within bone and beyond.
Kaplan RN. et al, (2006), Cancer Metastasis Rev, 25, 521 - 529
Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group.
Gogas H. et al, (2006), Ann Oncol, 17, 1835 - 1841
Insights into therapeutic mechanisms: Measuring immature platelet fraction (IPF) describes response to treatment in immune thrombocytopenic purpura (ITP).
Psaila B. et al, (2006), BLOOD, 108, 319A - 319A
High-risk melanoma with nodal involvement in a young woman.
Khan O. and Middleton M., (2006), Nat Clin Pract Oncol, 3, 517 - 521
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours.
Greystoke A. et al, (2006), Ann Oncol, 17, 1313 - 1319